Since deregulation of PTEN is one of the most common aberrations in many different human cancers, and our results show that PTEN-mediated regulation of Maf1 is not cell-type specific, a reduction in Maf1 expression is likely to be observed in many other types of cancers that possess alterations in PTEN function or mutations that activate PI3K signaling. This evidence concerns the gene MAF1 and cancer.